Risk status of patients with peripheral arterial disease (PAD);Alsó végtagi obliteratív versoérbetegek rizikóstátusa

Orvosi Hetilap

Volumn 148, Issue 52, 2007, Pages 2469-2476

  Jassó, István ^a,c   Landi, Anna ^a   Dinya, Elek ^b  

^a Fovarosi Egyesitett Szent Istvan es Szent Laszlo Korhaz   (Hungary)

^b EGIS PHARMACEUTICALS LTD   (Hungary)

^c NONE   (Hungary)

Author keywords

Peripheral arterial disease; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CLOPIDOGREL; CREATININE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE; TRIACYLGLYCEROL; URIC ACID;

ARTERY DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PATHOGENESIS; PLASMA VISCOSITY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SMOKING;

EID: 38349143648     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2007.28257     Document Type: Article

References (46)

1. Aronow, W. S.: Management of Peripheral Arterial Disease. Cardiol. Rev., 2005, 13, 61-68.
2. Belch, J. J. F., Topol, E. J., Agnelli, J. és mtsai: Critical Issues in Peripheral Arterial Disease detection and Management. A Call to Action. Arch. Intern. Med., 2003, 163, 884-892.
3. Zheng, Z.-J., Sharrett, A. R., Chambless, L. E. és mtsai: Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis, 1999, 131, 115-125.
4. Dormandy, J., Heeck, L., Vig, S.: Intermittent Claudication: A Condition With Underrated Risk. Semin. Vasc. Surg., 1999, 12, 96-208.
5. Hooi, J. D., Kester, A. D. M., Stoffers, H. E. J. H. és mtsai: Incidence of and Risk Factors for Asymptomatic Arterial Occlusive Disease: A Longitudinal Study. Am. J. Epidemiol., 2001, 153, 666-672.
6. Violi, F., Criqui, M., Longoni, A. és mtsai: Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A. D. E. P. study. Atherosclerosis, 1996, 120, 25-35.
7. Hirsch, A. T., Criqui, M. H., Treat-Jacobson, D. és mtsai: Peripheral arterial Disease Detection, Awareness, and Treatment in Primary Care. JAMA, 2001, 286, 1317-1323.
8. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348, 1329-1339.
9. Pedersen, T. R., Kjekshus, J., Pyörälä, K. és mtsai: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am. J. Cardiol., 1998, 81, 333-335.
10. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.
11. Youssef, F., Gupta, P., Mikhailidis, D. P. és mtsa: Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective survey. Angiology, 2005, 56, 279-287.
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
13. II. Magyar Terápiás Konszenzus a kardiovaszkuláris betegségek megelozésérol és preventív kezelésérol. Metabolizmus, 2005, Suppl. A, A1-A76.
14. Hale, W. E., Marks, R. G., May, F. E. és mtsai: Epidemiology of intermittent claudication: evaluation of risk factors. Age Ageing, 1988, 17, 57-60.
15. Hughson, W., Mann, J., Garrod, A.: Intermittent claudication: prevalence and risk factors. Br. Med. J., 1978, 1, 1379-1381.
16. Reunanen, A., Takkunen, H., Aromaa, A.: Prevalence of intermittent claudication and its effect on mortality. Acta Med. Scand., 1982, 211, 249-256.
17. Stoffers, H. E., Kester, A. D., Kajser, V. és mtsai: The prevalence of asymptomatic and unrecognised peripheral arterial occlusive disease. Int. J. Epidemiol., 1996, 25, 282-290.
18. Dormandy, J., Heeck, L., Vig, S.: Lower-extremity Arteriosclerosis as a Reflexion of a Systemic Process: Implications for Concomittant Coronary and Carotid Disease. Sem. Vasc. Surg., 1999, 12, 118-122.
19. Levy, P. J., Jackson, S. A., McCoy, T. P. és mtsa: Clinical caracteristic of patients with premature lower extremity atherosclerosis associated with familial early cardiovascular disease and/or cancer. Int. Ang., 2006, 25, 304-309.
20. Bhatt, D. L., Steg, P. G., Ohman, E. M. és mtsai, REACH Registry Investigators: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA, 2006, 295, 180-189.
21. Szomják E., Dér H., Veres K. és mtsai: Perifériás érbetegeink klinikai adatainak elemzése, különös tekintettel a kor- és nembeli sajátosságokra, valamint az intervenciós radiológiai beavatkozások késoi eredményeire. Magy. Belorv. Arch., 2006, 61, 260-266.
22. Fowkes, F. G. R., Houtley, E., Carwod, E. H. H. és mtsai: Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol., 1990, 20, 384-392.
23. Kannel W., Wolf P., Castelli W. D. és mtsai: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA, 1987, 258, 1183-1186.
24. Tsiara, S., Elisaf, M., Mikhailidis, D. P.: Influence of Smoking on Predictors of Vascular Disease. Angiology, 2003, 54, 507-530.
25. Fowkes, F. G. R., Housley, E., Riemersma, R. A. és mtsai: Smoking, Lipids, Glucose Intolerance, and Blood Pressure as Risk Factors for peripheral Atherosclerosis Compared with Ischemic heart Disease in the Edinburgh Artery Study. Am. J. Epidemiol., 1992, 135, 331-340.
26. Ridker, P. M., Stampfer, M. J., Rifai, N.: Novel Risk Factors for Systemic Atherosclerosis. A Comparison of C-Reactive Protein, Fibrinigen, Homocysteine, Lipoprotein (a), and Standard Cholesterol Screening as Predictors of Peripheral Arterial Disease. JAMA, 2001, 285, 2481-2485.
27. Landi A.: Az arteriosclerosis obliterans humorális syndromája és annak összefüggései klinikai, kockázati és prognosztikai tényezokkel. Kandidátusi értekezés, 1994.
28. Murabito, J. M., D'Agostino, R. B., Silbershatz, H. és mtsa: Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation, 1997, 96, 44-49.
29. Kannel, W. B., McGee, D. L: Update on some epidemiological features of intermittent calaudication. J. Am. Geriatr. Soc., 1985, 33, 13-18.
30. Taute, B.-M., Taute, R., Heins, S. és mtsai: Hyperhomocysteinemia: marker of systemic atherosclerosis in peripheral arterial disease. Int. Ang., 2004, 23, 35-40.
31. Hirsch, A. T., Haskal, Z. J., Hertzer, N. R. és mtsai: ACC/ AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,* Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/ AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic InterSociety Consensus; and Vascular Disease Foundation. Circulation, 2006, 113, e463-e465.
32. Culleton, B. F., Larson, M. G., Evans, J. C. és mtsai: Prevalence and Correlates of Elevated Serum Creatinine Levels. The Framingham Heart Study. Arch. Intern. Med., 1999, 159, 1785-1790.
33. Bleyer, A. J., Shemanski, L. R., Burke, G. L. és mtsai: Tobacco, hypertension, and vascular disease: Risk factors for renal functional decline in an older population. Kid. Int., 2000, 57, 2072-2079.
34. Ernst, E.: Fibrinogen: Its Emerging Role as a Cardiovascular Risk Factor. Angiology, 1994, 45, 87-93.
35. Sellmayer, A., Limmert, T., Hoffmann, U.: High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useftil screening? Int. Angiol., 2003, 22, 15-23.
36. Ridker, P. M.: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 2001, 103, 1813-1818.
37. Ridker, P. M., Cook, N.: Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores. Circulation, 2004, 109, 1955-1959.
38. Dösa E., Szabö A., Entz L. és mtsai: Az ultraszenzitív módszerrel meghatározott C-reaktív fehérjekoncentráció megoszlása az egészséges magyar populációban. Orv. Hetil., 2004, 145, 567-572.
39. Ridker, P. M., Cushman, M., Stampfer, M. J. és mtsai: Plasma Concentration of C-Reactive Protein and Risk of Developing Peripheral Vascular Disease. Circulation, 1998, 97, 425-428.
40. Vainas, T., Stassen, F. R. M, de Graaf, R. és mtsai: C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events. J. Vasc. Surg., 2005, 42, 243-51.
41. Malinow, M. R., Kang, S. S., Taylor, L. M. és mtsai: Prevalence of Hyperhomocyst(e)inemia in Patients With Peripheral Arterial Occlusive Disease. Circulation, 1989, 79, 1180-1188.
42. Mölgaard, J., Malinow, M. R., Lassvik, C és mtsai: Hyperhomocyst(e)inemia: an independent risk factor for intermittent claudication. J. Int. Med., 1992, 231, 273-279.
43. Thambyrajah, J., Townend, J. N.: Homocysteine and atherothrombosis - mechanism for injury. Eur. Heart J., 2000, 21, 967-974.
44. Bogye G., Alfthan, G., Antti, A. és mtsa: Egészséges középkorú férfiak plazma homocystein koncentrációja és ennek feltételezett kapcsolata a szív- és érrendszeri halálozással. Orv. Hetil., 1999, 140, 1573-1577.
45. Márk L., Erdei F., Márki-Zay J. és mtsai: A plazma-homociszteinszint vizsgálata ischaemiás szívbetegekben. Orv. Hetil., 2001, 142, 1611-1615.
46. Fang, J., Alderman, M. H.: Serum Uric Acid and Cardiovascular Mortality. The NHANES I Epidemiologic Follow-up Study, 1971-1992. JAMA, 2000, 283, 2404-2410.